Researchers at BioMarin Pharmaceutical have created a controversial drug that helps regulate bone development in children with the most common type of dwarfism. But some argue it’s a profit-driven solution in search of a problem.
Host Tonya Mosley talks with reporter Damian Garde (@damiangarde), who has been covering the story for our partners at STAT, the health and medicine publication.
This article was originally published on WBUR.org.
Copyright 2021 NPR. To see more, visit https://www.npr.org.